The DOI matches its Crossref record; 238 of the 238 references it cites were found in a registry or an index.
Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis
Open accessAbstract
SGLT2 (sodium-glucose cotransporter 2) inhibitors produce a distinctive pattern of benefits on the evolution and progression of cardiomyopathy and nephropathy, which is characterized by a reduction in oxidative and endoplasmic reticulum stress, restoration of mitochondrial health and enhanced mitochondrial biogenesis, a decrease in proinflammatory and profibrotic pathways, and preservation of cellular and organ integrity and viability. A substantial body of evidence indicates that this characteristic pattern of responses can be explained by the action of SGLT2 inhibitors to promote cellular housekeeping by enhancing autophagic flux, an effect that may be related to the action of these drugs to produce simultaneous upregulation of nutrient deprivation signaling and downregulation of nutrient surplus signaling, as manifested by an increase in the expression and activity of AMPK (adenosine monophosphate–activated protein kinase), SIRT1 (sirtuin 1), SIRT3 (sirtuin 3), SIRT6 (sirtuin 6), and PGC1-α (peroxisome proliferator–activated receptor γ coactivator 1-α) and decreased activation of mTOR (mammalian target of rapamycin). The distinctive pattern of cardioprotective and renoprotective effects of SGLT2 inhibitors is abolished by specific inhibition or knockdown of autophagy, AMPK, and sirtuins. In the clinical setting, the pattern of differentially increased proteins identified in proteomics analyses of blood collected in randomized trials is consistent with these findings. Clinical studies have also shown that SGLT2 inhibitors promote gluconeogenesis, ketogenesis, and erythrocytosis and reduce uricemia, the hallmarks of nutrient deprivation signaling and the principal statistical mediators of the ability of SGLT2 inhibitors to reduce the risk of heart failure and serious renal events. The action of SGLT2 inhibitors to augment autophagic flux is seen in isolated cells and tissues that do not express SGLT2 and are not exposed to changes in environmental glucose or ketones and may be related to an ability of these drugs to bind directly to sirtuins or mTOR. Changes in renal or cardiovascular physiology or metabolism cannot explain the benefits of SGLT2 inhibitors either experimentally or clinically. The direct molecular effects of SGLT2 inhibitors in isolated cells are consistent with the concept that SGLT2 acts as a nutrient surplus sensor, and thus, its inhibition causes enhanced nutrient deprivation signaling and its attendant cytoprotective effects, which can be abolished by specific inhibition or knockdown of AMPK, sirtuins, and autophagic flux.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationTargeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849
AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity
Cantó, C., Gerhart-Hines, Z., Feige, J. N., Lagouge, M., Noriega, L., Milne, J. C., Elliott, P. J., Puigserver, P., & Auwerx, J. (2009) · Nature · doi:10.1038/nature07813 · Cited by 3,300
Autophagy in immunity and inflammation
Levine, B., Mizushima, N., & Virgin, H. W. (2011) · Nature · doi:10.1038/nature09782 · Cited by 3,289
Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1
Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P., Spiegelman, B. M., & Puigserver, P. (2005) · Nature · doi:10.1038/nature03354 · Cited by 3,160
Biological Functions of Autophagy Genes: A Disease Perspective
Levine, B., & Kroemer, G. (2019) · Cell · doi:10.1016/j.cell.2018.09.048 · Cited by 2,832
AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α
Jäger, S., Handschin, C., St.-Pierre, J., & Spiegelman, B. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705070104 · Cited by 2,491
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096
Kalantar-Zadeh, K. (2017) · American Journal of Nephrology · doi:10.1159/000455387 · Cited by 1,148
Mizushima, N., & Levine, B. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2022774 · Cited by 1,140
Metabolic control of autophagy
Galluzzi, L., Pietrocola, F., Levine, B., & Kroemer, G. (2014) · Cell · doi:10.1016/j.cell.2014.11.006 · Cited by 855
mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype
Herranz, N., Gallage, S., Mellone, M., Wuestefeld, T., Klotz, S., Hanley, C. J., Raguz, S., Acosta, J. C., Innes, A. J., Banito, A., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3225 · Cited by 788
Cardiac autophagy is a maladaptive response to hemodynamic stress
Zhu, H., Tannous, P., Johnstone, J. L., Kong, Y., Shelton, J. M., Richardson, J. A., Le, V., Levine, B., Rothermel, B. A., & Hill, J. A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci27523 · Cited by 764
Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Heise, T., Bizzotto, R., Mari, A., Pieber, T. R., & Muscelli, E. (2016) · Diabetes · doi:10.2337/db15-1356 · Cited by 712
Baartscheer, A., Schumacher, C. A., Wüst, R. C. I., Fiolet, J. W. T., Stienen, G. J. M., Coronel, R., & Zuurbier, C. J. (2017) · Diabetologia · doi:10.1007/s00125-016-4134-x · Cited by 661
Santos-Gallego, C. G., Requena-Ibanez, J. A., San Antonio, R., Ishikawa, K., Watanabe, S., Picatoste, B., Flores, E., Garcia-Ropero, A., Sanz, J., Hajjar, R. J., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.056 · Cited by 651
Uthman, L., Baartscheer, A., Bleijlevens, B., Schumacher, C. A., Fiolet, J. W. T., Koeman, A., Jancev, M., Hollmann, M. W., Weber, N. C., Coronel, R., et al. (2018) · Diabetologia · doi:10.1007/s00125-017-4509-7 · Cited by 610
Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure
Swedberg, K., Young, J. B., Anand, I. S., Cheng, S., Desai, A. S., Diaz, R., Maggioni, A. P., McMurray, J. J. V., O'Connor, C., Pfeffer, M. A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214865 · Cited by 592
Zhou, H., Wang, S., Zhu, P., Hu, S., Chen, Y., & Ren, J. (2018) · Redox Biology · doi:10.1016/j.redox.2017.12.019 · Cited by 550 · cited 1×
“…cells Only canagliflozin increased activity of AMPK Effect of canagliflozin to reduce proinflammatory signaling was attenuated by AMPK knockout Zhou et al. (2018)192 Empagliflozin Cardiac microvascular endothelial cells from diabetic mice Increased AMPK phosphorylation Reduction in cardiac…”
BackgroundThe Role of Autophagy in the Heart
Sciarretta, S., Maejima, Y., Zablocki, D., & Sadoshima, J. (2018) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021317-121427 · Cited by 547
mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice
Inoki, K., Mori, H., Wang, J., Suzuki, T., Hong, S., Yoshida, S., Blattner, S. M., Ikenoue, T., Rüegg, M. A., Hall, M. N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44771 · Cited by 538
Nielsen, R., Møller, N., Gormsen, L. C., Tolbod, L. P., Hansson, N. H., Sorensen, J., Harms, H. J., Frøkiær, J., Eiskjaer, H., Jespersen, N. R., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.036459 · Cited by 518
Hallow, K. M., Helmlinger, G., Greasley, P. J., McMurray, J. J. V., & Boulton, D. W. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13126 · Cited by 499
Xu, L., Nagata, N., Nagashimada, M., Zhuge, F., Ni, Y., Chen, G., Mayoux, E., Kaneko, S., & Ota, T. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.05.028 · Cited by 493
Gangloff, Y.-G., Mueller, M., Dann, S. G., Svoboda, P., Sticker, M., Spetz, J.-F., Um, S. H., Brown, E. J., Cereghini, S., Thomas, G., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.21.9508-9516.2004 · Cited by 485
AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function
Dugan, L. L., You, Y.-H., Ali, S. S., Diamond-Stanic, M., Miyamoto, S., DeCleves, A.-E., Andreyev, A., Quach, T., Ly, S., Shekhtman, G., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66218 · Cited by 456
Haq, S., Choukroun, G., Lim, H., Tymitz, K. M., del Monte, F., Gwathmey, J., Grazette, L., Michael, A., Hajjar, R., Force, T., et al. (2001) · Circulation · doi:10.1161/01.cir.103.5.670 · Cited by 440
Lee, M. M. Y., Brooksbank, K. J. M., Wetherall, K., Mangion, K., Roditi, G., Campbell, R. T., Berry, C., Chong, V., Coyle, L., Docherty, K. F., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.052186 · Cited by 437
Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects
Griffin, M., Rao, V. S., Ivey-Miranda, J., Fleming, J., Mahoney, D., Maulion, C., Suda, N., Siwakoti, K., Ahmad, T., Jacoby, D., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.045691 · Cited by 414
Targeting Mitochondria-Inflammation Circuit by β-Hydroxybutyrate Mitigates HFpEF
Deng, Y., Xie, M., Li, Q., Xu, X., Ou, W., Zhang, Y., Xiao, H., Yu, H., Zheng, Y., Liang, Y., et al. (2021) · Circulation Research · doi:10.1161/circresaha.120.317933 · Cited by 409
SIRT1 Negatively Regulates the Mammalian Target of Rapamycin
Ghosh, H. S., McBurney, M., & Robbins, P. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009199 · Cited by 397
Hawley, S. A., Ford, R. J., Smith, B. K., Gowans, G. J., Mancini, S. J., Pitt, R. D., Day, E. A., Salt, I. P., Steinberg, G. R., & Hardie, D. G. (2016) · Diabetes · doi:10.2337/db16-0058 · Cited by 391
Empagliflozin Increases Cardiac Energy Production in Diabetes
Verma, S., Rawat, S., Ho, K. L., Wagg, C. S., Zhang, L., Teoh, H., Dyck, J. E., Uddin, G. M., Oudit, G. Y., Mayoux, E., et al. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.07.006 · Cited by 386
Tomita, I., Kume, S., Sugahara, S., Osawa, N., Yamahara, K., Yasuda-Yamahara, M., Takeda, N., Chin-Kanasaki, M., Kaneko, T., Mayoux, E., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.06.020 · Cited by 376
Mazer, C. D., Hare, G. M. T., Connelly, P. W., Gilbert, R. E., Shehata, N., Quan, A., Teoh, H., Leiter, L. A., Zinman, B., Jüni, P., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044235 · Cited by 371
Vallon, V., Rose, M., Gerasimova, M., Satriano, J., Platt, K. A., Koepsell, H., Cunard, R., Sharma, K., Thomson, S. C., & Rieg, T. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00409.2012 · Cited by 370
Quagliariello, V., De Laurentiis, M., Rea, D., Barbieri, A., Monti, M. G., Carbone, A., Paccone, A., Altucci, L., Conte, M., Canale, M. L., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01346-y · Cited by 367
van Bommel, E. J. M., Muskiet, M. H. A., van Baar, M. J. B., Tonneijck, L., Smits, M. M., Emanuel, A. L., Bozovic, A., Danser, A. H. J., Geurts, F., Hoorn, E. J., et al. (2020) · Kidney International · doi:10.1016/j.kint.2019.09.013 · Cited by 363
Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
Ferrannini, G., Hach, T., Crowe, S., Sanghvi, A., Hall, K. D., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-0355 · Cited by 359
MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice
Zhang, D., Contu, R., Latronico, M. V. G., Zhang, J. L., Rizzi, R., Catalucci, D., Miyamoto, S., Huang, K., Ceci, M., Gu, Y., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43008 · Cited by 337
Acetylation in the regulation of autophagy
Xu, Y., & Wan, W. (2023) · Autophagy · doi:10.1080/15548627.2022.2062112 · Cited by 307
Wu, S., Lu, Q., Ding, Y., Wu, Y., Qiu, Y., Wang, P., Mao, X., Huang, K., Xie, Z., & Zou, M.-H. (2019) · Circulation · doi:10.1161/circulationaha.118.033552 · Cited by 298
Nasiri-Ansari, N., Nikolopoulou, C., Papoutsi, K., Kyrou, I., Mantzoros, C. S., Kyriakopoulos, G., Chatzigeorgiou, A., Kalotychou, V., Randeva, M. S., Chatha, K., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020818 · Cited by 297
Shao, Q., Meng, L., Lee, S., Tse, G., Gong, M., Zhang, Z., Zhao, J., Zhao, Y., Li, G., & Liu, T. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0964-4 · Cited by 293
Nassif, M. E., Qintar, M., Windsor, S. L., Jermyn, R., Shavelle, D. M., Tang, F., Lamba, S., Bhatt, K., Brush, J., Civitello, A., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.052503 · Cited by 281
Zannad, F., Ferreira, J. P., Pocock, S. J., Zeller, C., Anker, S. D., Butler, J., Filippatos, G., Hauske, S. J., Brueckmann, M., Pfarr, E., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051685 · Cited by 280
Self-citationRegulation of Akt Signaling by Sirtuins: Its Implication in Cardiac Hypertrophy and Aging
Pillai, V. B., Sundaresan, N. R., & Gupta, M. P. (2014) · Circulation Research · doi:10.1161/circresaha.113.300536 · Cited by 261
Cai, C., Guo, Z., Chang, X., Li, Z., Wu, F., He, J., Cao, T., Wang, K., Shi, N., Zhou, H., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102288 · Cited by 261
Han, Y.-C., Tang, S.-Q., Liu, Y.-T., Li, A.-M., Zhan, M., Yang, M., Song, N., Zhang, W., Wu, X.-Q., Peng, C.-H., et al. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-04184-8 · Cited by 257
Li, J., Liu, H., Takagi, S., Nitta, K., Kitada, M., Srivastava, S. P., Takagaki, Y., Kanasaki, K., & Koya, D. (2020) · JCI Insight · doi:10.1172/jci.insight.129034 · Cited by 245
Mordi, N. A., Mordi, I. R., Singh, J. S., McCrimmon, R. J., Struthers, A. D., & Lang, C. C. (2020) · Circulation · doi:10.1161/circulationaha.120.048739 · Cited by 244
Mancini, S. J., Boyd, D., Katwan, O. J., Strembitska, A., Almabrouk, T. A., Kennedy, S., Palmer, T. M., & Salt, I. P. (2018) · Scientific Reports · doi:10.1038/s41598-018-23420-4 · Cited by 240
Liang, Y., Arakawa, K., Ueta, K., Matsushita, Y., Kuriyama, C., Martin, T., Du, F., Liu, Y., Xu, J., Conway, B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030555 · Cited by 240
Blood ketone bodies in congestive heart failure
Lommi, J., Kupari, M., Koskinen, P., Näveri, H., Leinonen, H., Pulkki, K., & Härkönen, M. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(96)00214-8 · Cited by 234
SGLT2 Inhibitor–Induced Sympathoinhibition
Herat, L. Y., Magno, A. L., Rudnicka, C., Hricova, J., Carnagarin, R., Ward, N. C., Arcambal, A., Kiuchi, M. G., Head, G. A., Schlaich, M. P., et al. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.11.007 · Cited by 233
SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms
Osataphan, S., Macchi, C., Singhal, G., Chimene-Weiss, J., Sales, V., Kozuka, C., Dreyfuss, J. M., Pan, H., Tangcharoenpaisan, Y., Morningstar, J., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123130 · Cited by 228
Shimizu, W., Kubota, Y., Hoshika, Y., Mozawa, K., Tara, S., Tokita, Y., Yodogawa, K., Iwasaki, Y.-K., Yamamoto, T., Takano, H., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01127-z · Cited by 228
Liu, D., Ma, Z., Di, S., Yang, Y., Yang, J., Xu, L., Reiter, R. J., Qiao, S., & Yuan, J. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.08.032 · Cited by 225
Mustroph, J., Wagemann, O., Lücht, C. M., Trum, M., Hammer, K. P., Sag, C. M., Lebek, S., Tarnowski, D., Reinders, J., Perbellini, F., et al. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12336 · Cited by 225
Gao, G., Chen, W., Yan, M., Liu, J., Luo, H., Wang, C., & Yang, P. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4407 · Cited by 219
PGC-1α and ERRα target gene downregulation is a signature of the failing human heart
Sihag, S., Cresci, S., Li, A. Y., Sucharov, C. C., & Lehman, J. J. (2009) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2008.10.025 · Cited by 214
Obesity-Mediated Autophagy Insufficiency Exacerbates Proteinuria-induced Tubulointerstitial Lesions
Yamahara, K., Kume, S., Koya, D., Tanaka, Y., Morita, Y., Chin-Kanasaki, M., Araki, H., Isshiki, K., Araki, S.-I., Haneda, M., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012111080 · Cited by 213
Tian, J., Zhang, M., Suo, M., Liu, D., Wang, X., Liu, M., Pan, J., Jin, T., & An, F. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16601 · Cited by 212
Onishi, A., Fu, Y., Patel, R., Darshi, M., Crespo-Masip, M., Huang, W., Song, P., Freeman, B., Kim, Y. C., Soleimani, M., et al. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00264.2020 · Cited by 206
Philippaert, K., Kalyaanamoorthy, S., Fatehi, M., Long, W., Soni, S., Byrne, N. J., Barr, A., Singh, J., Wong, J., Palechuk, T., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.053350 · Cited by 204
Zannad, F., Ferreira, J. P., Butler, J., Filippatos, G., Januzzi, J. L., Sumin, M., Zwick, M., Saadati, M., Pocock, S. J., Sattar, N., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac495 · Cited by 201
Self-citationA Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes
van Zuydam, N. R., Ahlqvist, E., Sandholm, N., Deshmukh, H., Rayner, N. W., Abdalla, M., Ladenvall, C., Ziemek, D., Fauman, E., Robertson, N. R., et al. (2018) · Diabetes · doi:10.2337/db17-0914 · Cited by 195
Empagliflozin protects heart from inflammation and energy depletion via AMPK activation
Koyani, C. N., Plastira, I., Sourij, H., Hallström, S., Schmidt, A., Rainer, P. P., Bugger, H., Frank, S., Malle, E., & von Lewinski, D. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104870 · Cited by 194
Nakamura, T. Y., Iwata, Y., Arai, Y., Komamura, K., & Wakabayashi, S. (2008) · Circulation Research · doi:10.1161/circresaha.108.175141 · Cited by 186
Pessoa, T. D., Campos, L. C. G., Carraro-Lacroix, L., Girardi, A. C. C., & Malnic, G. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013060588 · Cited by 184
Bae, H. R., Kim, D. H., Park, M. H., Lee, B., Kim, M. J., Lee, E. K., Chung, K. W., Kim, S. M., Im, D. S., & Chung, H. Y. (2016) · Oncotarget · doi:10.18632/oncotarget.12119 · Cited by 181
Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Barsotti, E., Clerico, A., & Muscelli, E. (2017) · Diabetes Care · doi:10.2337/dc16-2724 · Cited by 181
Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure
Boorsma, E. M., Beusekamp, J. C., ter Maaten, J. M., Figarska, S. M., Danser, A. H. J., van Veldhuisen, D. J., van der Meer, P., Heerspink, H. J. L., Damman, K., & Voors, A. A. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2066 · Cited by 177
Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
Chang, Y.-K., Choi, H., Jeong, J. Y., Na, K.-R., Lee, K. W., Lim, B. J., & Choi, D. E. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158810 · Cited by 176
Fan, Y., Yang, Q., Yang, Y., Gao, Z., Ma, Y., Zhang, L., Liang, W., & Ding, G. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.29323 · Cited by 174
Yang, X., Liu, Q., Li, Y., Tang, Q., Wu, T., Chen, L., Pu, S., Zhao, Y., Zhang, G., Huang, C., et al. (2020) · Adipocyte · doi:10.1080/21623945.2020.1807850 · Cited by 172
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Pocock, S. J., Sattar, N., Brueckmann, M., Jamal, W., Cotton, D., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.01.033 · Cited by 172
Self-citationMizuno, M., Kuno, A., Yano, T., Miki, T., Oshima, H., Sato, T., Nakata, K., Kimura, Y., Tanno, M., & Miura, T. (2018) · Physiological Reports · doi:10.14814/phy2.13741 · Cited by 169
Neeland, I. J., McGuire, D. K., Chilton, R., Crowe, S., Lund, S. S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115616901 · Cited by 168
Mori, H., Inoki, K., Masutani, K., Wakabayashi, Y., Komai, K., Nakagawa, R., Guan, K.-L., & Yoshimura, A. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.04.136 · Cited by 165
Aragón-Herrera, A., Feijóo-Bandín, S., Otero Santiago, M., Barral, L., Campos-Toimil, M., Gil-Longo, J., Costa Pereira, T. M., García-Caballero, T., Rodríguez-Segade, S., Rodríguez, J., et al. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113677 · Cited by 163
Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure
Petersson, M., Friberg, P., Eisenhofer, G., Lambert, G. W., & Rundqvist, B. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi184 · Cited by 162
Umino, H., Hasegawa, K., Minakuchi, H., Muraoka, H., Kawaguchi, T., Kanda, T., Tokuyama, H., Wakino, S., & Itoh, H. (2018) · Scientific Reports · doi:10.1038/s41598-018-25054-y · Cited by 162
Xu, C., Wang, W., Zhong, J., Lei, F., Xu, N., Zhang, Y., & Xie, W. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.03.013 · Cited by 161
Gaborit, B., Ancel, P., Abdullah, A. E., Maurice, F., Abdesselam, I., Calen, A., Soghomonian, A., Houssays, M., Varlet, I., Eisinger, M., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01237-2 · Cited by 160
Zhang, T., Chi, Y., Kang, Y., Lu, H., Niu, H., Liu, W., & Li, Y. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27306 · Cited by 159
Vörös, G., Ector, J., Garweg, C., Droogné, W., Cleemput, J. V., Peersman, N., Vermeersch, P., & Janssens, S. P. (2018) · Circulation Heart Failure · doi:10.1161/circheartfailure.118.004953 · Cited by 156
Adamson, C., Docherty, K. F., Heerspink, H. J. L., de Boer, R. A., Damman, K., Inzucchi, S. E., Køber, L., Kosiborod, M., Martínez, F. A., Petrie, M. C., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.058910 · Cited by 155
Arab, H. H., Al‐Shorbagy, M. Y., & Saad, M. A. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109368 · Cited by 151
Yuan, Y., Ma, Z., Zhang, X., Xu, S., Zeng, X., Yang, Z., Deng, W., & Tang, Q. (2017) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2017.10.008 · Cited by 149
Chung, Y. J., Park, K. C., Tokar, S., Eykyn, T. R., Fuller, W., Pavlović, D., Swietach, P., & Shattock, M. J. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa323 · Cited by 149
Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes
Li, J., Woodward, M., Perkovic, V., Figtree, G. A., Heerspink, H. J. L., Mahaffey, K. W., de Zeeuw, D., Vercruysse, F., Shaw, W., Matthews, D. R., et al. (2020) · JACC: Heart Failure · doi:10.1016/j.jchf.2019.08.004 · Cited by 144
Oshima, H., Miki, T., Kuno, A., Mizuno, M., Sato, T., Tanno, M., Yano, T., Nakata, K., Kimura, Y., Abe, K., et al. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.253666 · Cited by 135
Liu, W. J., Shen, T. T., Chen, R. H., Wu, H.-L., Wang, Y. J., Deng, J. K., Chen, Q. H., Pan, Q., Huang Fu, C.-M., Tao, J.-L., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.666354 · Cited by 132
Xu, J., Kitada, M., Ogura, Y., Liu, H., & Koya, D. (2021) · Cells · doi:10.3390/cells10061457 · Cited by 131
Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes
Li, J., Neal, B., Perkovic, V., de Zeeuw, D., Neuen, B. L., Arnott, C., Simpson, R., Oh, R., Mahaffey, K. W., & Heerspink, H. J. L. (2020) · Kidney International · doi:10.1016/j.kint.2020.04.051 · Cited by 130
Liu, X., Xu, C., Xu, L., Li, X., Sun, H., Xue, M., Li, T., Yu, X., Sun, B., & Chen, L. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154334 · Cited by 130
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists
Shen, L., Kristensen, S. L., Bengtsson, O., Böhm, M., de Boer, R. A., Docherty, K. F., Inzucchi, S. E., Katova, T., Køber, L., Kosiborod, M., et al. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2020.11.009 · Cited by 128
Meng, Z., Liu, X., Li, T., Fang, T., Cheng, Y., Han, L., Sun, B., & Chen, L. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107492 · Cited by 128
Kogot-Levin, A., Hinden, L., Riahi, Y., Israeli, T., Tirosh, B., Cerasi, E., Mizrachi, E. B., Tam, J., Mosenzon, O., & Leibowitz, G. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107954 · Cited by 126 · cited 1×
“…tubular cells exposed to high glucose/palmitic acid Decreased mTOR phosphorylation and activation Decreased lipid accumulation in proximal tubular cells Kogot-Levin et al. (2020)87 Dapagliflozin Mouse model of diabetic nephropathy, LLC-PK1, and HK2 proximal tubular cells Inhibition of mTORC1…”
BackgroundThe role of autophagy in cardiovascular pathology
Gatica, D., Chiong, M., Lavandero, S., & Klionsky, D. J. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab158 · Cited by 126
Dapagliflozin Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR Pathway
Li, L., Li, Q., Huang, W., Han, Y., Tan, H., An, M., Xiang, Q., Zhou, R., Yang, L., & Cheng, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.589273 · Cited by 126
Effects of canagliflozin on human myocardial redox signalling: clinical implications
Kondo, H., Akoumianakis, I., Badi, I., Akawi, N. A., Kotanidis, C. P., Polkinghorne, M., Stadiotti, I., Sommariva, E., Antonopoulos, A. S., Carena, M. C., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab420 · Cited by 124
Birnbaum, Y., Bajaj, M., Yang, H., & Ye, Y. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6778-x · Cited by 123
Giugliano, D., Longo, M., Scappaticcio, L., Bellastella, G., Maiorino, M. I., & Esposito, K. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01430-3 · Cited by 122
Li, X., Lü, Q., Qiu, Y., do Carmo, J. M., Wang, Z., da Silva, A. A., Mouton, A. J., Omoto, A. C. M., Hall, M. E., Li, J., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.018298 · Cited by 120
D’Onofrio, N., Sardu, C., Trotta, M. C., Scisciola, L., Turriziani, F., Ferraraccio, F., Panarese, I., Petrella, L., Fanelli, M., Modugno, P., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101337 · Cited by 116
Dapagliflozin Attenuates Na+/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation
Ye, Y., Jia, X., Bajaj, M., & Birnbaum, Y. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6837-3 · Cited by 115
Packer, M. (2020) · Circulation · doi:10.1161/circulationaha.119.045561 · Cited by 115
Self-citationClinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis
López‐Sainz, Á., Domínguez, F., Lopes, L. R., Ochoa, J. P., Villa, R. B., Climent, V. E., Linschoten, M., Tirón, C., Chiriatti, C., Marques, N. S., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.029 · Cited by 115
Korbut, A. I., Taskaeva, I. S., Bgatova, N. P., Muraleva, N. A., Орлов, Н. Б., Dashkin, M. V., Khotskina, А. S., Zavyalov, E. L., Konenkov, V. I., Klein, T., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082987 · Cited by 113
Yu, Y., Que, J., Liu, S., Huang, K., Lu, Q., Weng, Y., Rong, F., Wang, L., Zhou, Y., Xue, Y., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.768214 · Cited by 113
Renal Denervation Prevents Heart Failure Progression Via Inhibition of the Renin-Angiotensin System
Sharp, T. E., Polhemus, D. J., Li, Z., Spaletra, P. M., Jenkins, J. S., Reilly, J. P., White, C. J., Kapusta, D. R., Lefer, D. J., & Goodchild, T. T. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.08.2186 · Cited by 111
SIRT1 and SIRT3 Deacetylate Homologous Substrates: AceCS1,2 and HMGCS1,2
Hirschey, M. D., Shimazu, T., Capra, J. A., Pollard, K. S., & Verdin, E. M. (2011) · Aging · doi:10.18632/aging.100339 · Cited by 110
Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline
Gorski, M., Jung, B., Li, Y., Matías‐García, P. R., Wuttke, M., Coassin, S., Thio, C. H. L., Kleber, M. E., Winkler, T. W., Wanner, V., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.09.030 · Cited by 108
Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial
Januzzi, J. L., Zannad, F. M., Anker, S. D., Butler, J., Filippatos, G. S., Pocock, S., Ferreira, J. P., Sattar, N. A., Verma, S., Vedin, O., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.046 · Cited by 108
Self-citationEmpagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway
Lü, Q., Liu, J., Li, X., Sun, X., Zhang, J., Ren, D., Tong, N., & Li, J. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110642 · Cited by 107
Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction
Omar, M., Jensen, J., Frederiksen, P. H., Kistorp, C., Videbæk, L. M., Poulsen, M. K., Möller, S., Ali, M., Gustafsson, F., Køber, L., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.10.005 · Cited by 107
Ren, C., Sun, K., Zhang, Y., Hu, Y.-X., Hu, B., Zhao, J., He, Z., Ding, R., Wang, W., & Liang, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.664181 · Cited by 107
Zanchi, A., Burnier, M., Muller, M., Wurzner-Ghajarzadeh, A., Maillard, M. P., Loncle, N., Milani, B., Dufour, N., Bonny, O., & Pruijm, M. T. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.016173 · Cited by 106
Byrne, N. J., Soni, S., Takahara, S., Ferdaoussi, M., Batran, R. A., Darwesh, A. M., Levasseur, J. L., Beker, D. L., Vos, D. Y., Schmidt, M. A., et al. (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.119.006573 · Cited by 105
Saito, T., Asai, K., Sato, S., Hayashi, M., Adachi, A., Sasaki, Y., Takano, H., Mizuno, K., & Shimizu, W. (2016) · Autophagy · doi:10.1080/15548627.2016.1145326 · Cited by 101
Targeting energy pathways in kidney disease: the roles of sirtuins, AMPK, and PGC1α
Clark, A. J., & Parikh, S. M. (2020) · Kidney International · doi:10.1016/j.kint.2020.09.037 · Cited by 101
Chen, R., Xu, M., Hogg, R. T., Li, J., Little, B. B., Gerard, R. D., & Garcia, J. A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.244780 · Cited by 99
Borges, F. A., dos Santos, D. S., Benetti, A., Polidoro, J. Z., Wisnivesky, A. C. T., Crajoinas, R. O., Antônio, E. L., Jensen, L., Caramelli, B., Malnic, G., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020071029 · Cited by 99
Bugyei‐Twum, A., Ford, C., Civitarese, R., Seegobin, J., Advani, S. L., Desjardins, J., Kabir, G., Zhang, Y., Mitchell, M., Switzer, J., et al. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy131 · Cited by 98
Wei, D., Liao, L., Wang, H., Zhang, W., Wang, T., & Xu, Z. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117414 · Cited by 98
SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney
Ke, Q., Shi, C., Lv, Y., Wang, L., Luo, J., Jiang, L., Yang, J., & Zhou, Y. (2021) · The FASEB Journal · doi:10.1096/fj.202100909rr · Cited by 96
Packer, M. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.08.015 · Cited by 95
Self-citationPolhemus, D. J., Trivedi, R. K., Gao, J., Li, Z., Scarborough, A. L., Goodchild, T. T., Varner, K. J., Xia, H., Smart, F. W., Kapusta, D. R., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.056 · Cited by 94
TLR9 and beclin 1 crosstalk regulates muscle AMPK activation in exercise
Liu, Y., Nguyen, P., Wang, X., Zhao, Y., Meacham, C. E., Zou, Z., Bordieanu, B., Johanns, M., Vertommen, D., Wijshake, T., et al. (2020) · Nature · doi:10.1038/s41586-020-1992-7 · Cited by 88
Tomczyk, M. M., Cheung, K. G., Xiang, B., Tamanna, N., Teixeira, A. L. F., Agarwal, P., Kereliuk, S. M., Spicer, V., Lin, L., Treberg, J. R., et al. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.008547 · Cited by 87
Kim, D. H., Park, M. H., Ha, S., Bang, E. J., Lee, Y., Lee, A. K., Lee, J., Yu, B. P., & Chung, H. Y. (2019) · Aging · doi:10.18632/aging.101838 · Cited by 86
Fitchett, D., Inzucchi, S. E., Zinman, B., Wanner, C., Schumacher, M., Schmoor, C., Ohneberg, K., Ofstad, A. P., Salsali, A., George, J. T., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13615 · Cited by 85
Zeng, C., Fan, Y., Wu, J., Shi, S., Chen, Z., Zhong, Y., Zhang, C., Zen, K., & Liu, Z. (2014) · The Journal of Pathology · doi:10.1002/path.4382 · Cited by 80
Manipulating Sirtuin 3 pathway ameliorates renal damage in experimental diabetes
Locatelli, M., Zoja, C., Zanchi, C., Corna, D., Villa, S., Bolognini, S., Novelli, R., Perico, L., Remuzzi, G., Benigni, A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-65423-0 · Cited by 78
Ala, M., Khoshdel, M. R. F., & Dehpour, A. R. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/1197061 · Cited by 78
Thiele, K., Rau, M., Hartmann, N. K., Möllmann, J., Jankowski, J., Böhm, M., Keszei, A. P., Marx, N., & Lehrke, M. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14517 · Cited by 77
Sung, M. M. Y., Zordoky, B. N. M., Bujak, A. L., Lally, J., Fung, D., Young, M. E., Horman, S., Miller, E. J., Light, P. E., Kemp, B. E., et al. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv166 · Cited by 76
Yin, Y., Jiang, C. S., Zhang, M., Jin, J., Ge, S., & Wang, X. (2019) · Aging · doi:10.18632/aging.101954 · Cited by 74
Uthman, L., Kuschma, M. C., Römer, G., Boomsma, M., Keßler, J., Hermanides, J., Hollmann, M. W., Preckel, B., Zuurbier, C. J., & Weber, N. C. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07083-w · Cited by 74
Treatment with D-β-hydroxybutyrate protects heart from ischemia/reperfusion injury in mice
Yu, Y., Yu, Y., Zhang, Y., Zhang, Z., An, W., & Zhao, X. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.04.019 · Cited by 73
Swe, M. T., Thongnak, L., Jaikumkao, K., Pongchaidecha, A., Chatsudthipong, V., & Lungkaphin, A. (2019) · Clinical Science · doi:10.1042/cs20190863 · Cited by 73
Faridvand, Y., Kazemzadeh, H., Vahedian, V., Mirzajanzadeh, P., Nejabati, H. R., Safaie, N., Maroufi, N. F., Pezeshkian, M., Nouri, M., & Jodati, A. (2022) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13638 · Cited by 73
Park, C. H., Lee, B., Han, M., Rhee, W. J., Kwak, M. S., Yoo, T., & Shin, J. (2022) · Cell Death Discovery · doi:10.1038/s41420-021-00801-9 · Cited by 72
Sirt6 deficiency results in progression of glomerular injury in the kidney
Huang, W., Liu, H., Zhu, S., Woodson, M., Liu, R., Tilton, R. G., Miller, J. D., & Zhang, W. (2017) · Aging · doi:10.18632/aging.101214 · Cited by 71
Ren, F., Xie, Z.-Y., Jiang, Y.-N., Guan, X., Chen, Q., Lai, T.-F., & Li, L. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00805-2 · Cited by 71
Ulk1-dependent alternative mitophagy plays a protective role during pressure overload in the heart
Nah, J., Shirakabe, A., Mukai, R., Zhai, P., Sung, E., Ivessa, A., Mizushima, W., Nakada, Y., Saito, T., Hu, C., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac003 · Cited by 71
Lim, J. H., Kim, H. W., Kim, M. Y., Kim, T. W., Kim, E. N., Kim, Y., Chung, S., Kim, Y. S., Choi, B. S., Kim, Y., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0324-4 · Cited by 69
Heart specific PGC-1α deletion identifies metabolome of cardiac restricted metabolic heart failure
Kärkkäinen, O. K., Tuomainen, T., Mutikainen, M., Lehtonen, M., Ruas, J. L., Hanhineva, K., & Tavi, P. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy155 · Cited by 67
Abdurrachim, D., Teo, X. Q., Woo, C. C., Chan, W. X., Lalic, J., Lam, C. S. P., & Lee, P. T. H. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13536 · Cited by 67
Tsogbadrakh, B., Ryu, H., Ju, K. D., Lee, J., Yun, S., Yu, K., Kim, H. J., Ahn, C., & Oh, K. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.12.159 · Cited by 67
Wang, C., Chen, C., Lin, M.-H., Su, H., Ho, M.-Y., Yeh, J., Tsai, M., Hsieh, C., & Wen, M. (2020) · Biology · doi:10.3390/biology9110369 · Cited by 67
Thirunavukarasu, S., Jex, N., Chowdhary, A., Hassan, I. U., Straw, S., Craven, T. P., Gorecka, M. M., Broadbent, D. A., Swoboda, P., Witte, K. K., et al. (2021) · Diabetes · doi:10.2337/db21-0270 · Cited by 64
mTOR-Activating Mutations in RRAGD Are Causative for Kidney Tubulopathy and Cardiomyopathy
Schlingmann, K. P., Jouret, F., Shen, K., Nigam, A., Arjona, F. J., Dafinger, C., Houillier, P., Jones, D. P., Kleinerüschkamp, F., Oh, J. S., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021030333 · Cited by 64
Increased NHE3 abundance and transport activity in renal proximal tubule of rats with heart failure
Inoue, B. H., dos SANTOS, L., Pessoa, T. D., Antônio, E. L., Pacheco, B. P. M., Savignano, F. A., Carraro‐Lacroix, L. R., Tucci, P. J. F., Malnic, G., & Girardi, A. C. C. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00127.2011 · Cited by 62
Mechanisms of Sodium–Glucose Cotransporter 2 Inhibition: Insights From Large-Scale Proteomics
Ferrannini, E., Murthy, A. C., Lee, Y., Muscelli, E., Weiss, S. J., Ostroff, R. M., Sattar, N. A., Williams, S. A., & Ganz, P. (2020) · Diabetes Care · doi:10.2337/dc20-0456 · Cited by 62
Yuan, L., Yuan, Y., Liu, F., Li, L., Liu, J., Chen, Y., Cheng, J., & Lu, Y. (2021) · Aging · doi:10.18632/aging.202653 · Cited by 61
Katsurada, K., Nandi, S. S., Sharma, N. M., & Patel, K. P. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.008365 · Cited by 61
Yang, L., Liang, B., Li, J., Zhang, X., Chen, H., Sun, J. M., & Zhang, Z. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110206 · Cited by 61
Renal mTORC1 activation is associated with disease activity and prognosis in lupus nephritis
Mao, Z., Tan, Y. C. R. S., Tao, J., Li, L., Wang, H., Yu, F., Perl, A., & Zhao, M. (2022) · Rheumatology · doi:10.1093/rheumatology/keac037 · Cited by 61
Dietary carbohydrates restriction inhibits the development of cardiac hypertrophy and heart failure
Nakamura, M., Odanovic, N. R., Nakada, Y., Dohi, S., Zhai, P., Ivessa, A., Yang, Z., Abdellatif, M., & Sadoshima, J. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa298 · Cited by 60
Impact of Autophagy on Prognosis of Patients With Dilated Cardiomyopathy
Kanamori, H., 吉田明弘, Naruse, G., Endo, S., Minatoguchi, S., Watanabe, T., Kawaguchi, T., Tanaka, T., Yamada, Y., Takasugi, N., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.059 · Cited by 60
SIRT1 prevents hyperuricemia via the PGC-1α/PPARγ-ABCG2 pathway
Wang, J., Zhu, X., Liu, L., Xue, Y., Yang, X., & Zou, H.-J. (2016) · Endocrine · doi:10.1007/s12020-016-0896-7 · Cited by 59
Inoue, M.-K., Matsunaga, Y., Nakatsu, Y., Yamamotoya, T., Ueda, K., Kushiyama, A., Sakoda, H., Fujishiro, M., Ono, H., Iwashita, M., et al. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0454-6 · Cited by 59
Jaikumkao, K., Promsan, S., Thongnak, L., Swe, M. T., Tapanya, M., Htun, K. T., Kothan, S., Intachai, N., & Lungkaphin, A. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30316 · Cited by 58
Causland, F. R. M., Lefkowitz, M. P., Claggett, B. L., Packer, M., Senni, M., Gori, M., Jhund, P. S., McGrath, M. M., Rouleau, J. L., Shi, V. C., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2421 · Cited by 58
Self-citationNandi, S. S., Duryee, M. J., Shahshahan, H. R., Thiele, G. M., Anderson, D. R., & Mishra, P. K. (2015) · PubMed · Cited by 55
FoxO-dependent and -independent mechanisms mediate SirT1 effects on IGFBP-1 gene expression
Gan, L., Han, Y.-S., Bastianetto, S., Dumont, Y., Unterman, T. G., & Quirion, R. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.169 · Cited by 54
Cardiac-Specific Overexpression of miR-222 Induces Heart Failure and Inhibits Autophagy in Mice
Su, M., Chen, Z., Changxin, W., Song, L., Zou, Y., Zhang, L., Hui, R., & Wang, J. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000447853 · Cited by 54
In Vivo RNA Interference Models of Inducible and Reversible Sirt1 Knockdown in Kidney Cells
Chuang, P. Y., Xu, J., Dai, Y., Fu, J., Mallipattu, S. K., Yacoub, R., Gu, L., Premsrirut, P. K., & He, C. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.03.016 · Cited by 52
Akkafa, F., Altıparmak, İ. H., Erkuş, M. E., Aksoy, N., Kaya, C., Ozer, A., Sezen, H., Öztuzcu, S., Koyuncu, İ., & Umurhan, B. (2015) · Redox Biology · doi:10.1016/j.redox.2015.07.011 · Cited by 51
Josephrajan, A., Hertzel, A. V., Bohm, E. K., McBurney, M. W., Imai, S., Mashek, D. G., Kim, D., & Bernlohr, D. (2019) · Diabetes · doi:10.2337/db18-1367 · Cited by 51
Sanz, M.-N., Grimbert, L., Moulin, M., Gressette, M., Rücker‐Martin, C., Lemaire, C., Mericskay, M., Veksler, V., Ventura‐Clapier, R., Garnier, A., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205005 · Cited by 51
Li, X., Flynn, E. R., do Carmo, J. M., Wang, Z., da Silva, A. A., Mouton, A. J., Omoto, A. C. M., Hall, M. E., & Hall, J. E. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.859253 · Cited by 51
Moellmann, J., Mann, P. A., Kappel, B. A., Kahles, F., Klinkhammer, B. M., Boor, P., Kramann, R., Ghesquière, B., Lebherz, C., Marx, N., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14814 · Cited by 51
Chiang, H., Lee, J., Huang, H., Huang, H. Y., Liu, H., & Huang, C. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14859 · Cited by 50
Tsai, K., Hsieh, P., Chou, W.-C., Cheng, H.-C., Huang, Y., & Chan, S. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00547-y · Cited by 50
Lee, J.-Y., Lee, M., Lee, J. Y., Bae, J., Shin, E., Lee, Y., Lee, B., Kang, E. S., & Soo, B. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0187 · Cited by 49
Xu, Z., Hu, W., Wang, B., Xu, T., Wang, J., & Wei, D. (2022) · Yonsei Medical Journal · doi:10.3349/ymj.2022.63.7.619 · Cited by 49
SIRT1 rs10823108 and FOXO1 rs17446614 responsible for genetic susceptibility to diabetic nephropathy
Zhao, Y., Wei, J., Hou, X., Liu, H., Guo, F., Zhou, Y., Zhang, Y., Qu, Y., Gu, J., Zhou, Y., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10612-7 · Cited by 47
Empagliflozin prevents from early cardiac injury post myocardial infarction in non-diabetic mice
Liu, Y., Wu, M., Xu, J., Xu, B., & Kang, L. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105788 · Cited by 47
The adrenergic regulation of proximal tubular Na + /H + exchanger 3 in the rat
Healy, V., Thompson, C., & Johns, E. J. (2013) · Acta Physiologica · doi:10.1111/apha.12181 · Cited by 46
Lee, C.-C., Chen, W.-T., Chen, S., & Lee, T. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114674 · Cited by 46
Chaperone-mediated autophagy protects cardiomyocytes against hypoxic-cell death
Ghosh, R., Gillaspie, J. J., Campbell, K. S., Symons, J. D., Boudina, S., & Pattison, J. S. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00369.2021 · Cited by 46
Wu, S., Lan, J., Li, L., Wang, X., Tong, M., Fu, L., Zhang, Y., Xu, J., Chen, X., Chen, H., et al. (2021) · Cell Biology and Toxicology · doi:10.1007/s10565-021-09649-2 · Cited by 45
Hu, Y.-X., Han, X.-S., & Jing, Q. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-0602-4_7 · Cited by 43
Vaduganathan, M., Ferreira, J. P., Rossignol, P., Neuen, B. L., Claggett, B. L., Pfeffer, M. A., McMurray, J. J. V., Pitt, B., Zannad, F. M., & Solomon, S. D. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2635 · Cited by 43
Filho, R. A. P., Girardi, A. C. C., Nishi, E. E., Campos, R. R., & Bergamaschi, C. T. (2015) · Experimental Physiology · doi:10.1113/ep085075 · Cited by 42
Sokolov, V. V., Yakovleva, T. A., Chu, L., Tang, W., Greasley, P. J., Johansson, S. A., Peskov, K. V., Helmlinger, G., Boulton, D. W., & Penland, R. C. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12498 · Cited by 42
Sun, P., Wang, Y., Ding, Y., Luo, J., Zhong, J., Xu, N., Zhang, Y., & Xie, W. (2021) · iScience · doi:10.1016/j.isci.2021.102521 · Cited by 42
Tian, G., Yu, Y., Deng, H., Liu, Y., Shi, X., & Yu, B. (2021) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13470 · Cited by 41
Gui, Z., Suo, C., Wang, Z., Zheng, M., Fei, S., Chen, H., Sun, L., Han, Z., Tao, J., Ju, X., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.650424 · Cited by 41
Meijles, D. N., Zoumpoulidou, G., Markou, T., Rostron, K. A., Patel, R. K., Lay, K., Handa, B. S., Wong, B., Sugden, P. H., & Clerk, A. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.02.006 · Cited by 40
Yang, X., Liu, Q., Li, Y., Ding, Y., Zhao, Y. H., Tang, Q., Wu, T., Chen, L., Pu, S., Cheng, S., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15381 · Cited by 40
Chi, P., Lee, C., Hsieh, Y.-J., Lu, C., & Hsu, B. (2022) · International Journal of Medical Sciences · doi:10.7150/ijms.69031 · Cited by 40
Nespoux, J., Patel, R. P., Zhang, H., Huang, W., Freeman, B., Sanders, P. W., Kim, Y. C., & Vallon, V. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00607.2019 · Cited by 39
Empagliflozin modulates renal sympathetic and heart rate baroreflexes in a rabbit model of diabetes
Gueguen, C., Burke, S. L., Barzel, B., Eikelis, N., Watson, A. M. D., Jha, J. C., Jackson, K. L., Sata, Y., Lim, K., Lambert, G. W., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05145-0 · Cited by 38
Zhang, Z., Ni, L., Zhang, L., Zha, D., Hu, C., Zhang, L., Feng, H. A., Wei, X., & Wu, X. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s289712 · Cited by 38
Cited by
Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association
Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., Coresh, J., Mathew, R. O., Baker-Smith, C. M., Carnethon, M. R., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001184 · Cited by 2,208
Heart Failure With Preserved Ejection Fraction
Borlaug, B. A., Sharma, K., Shah, S. J., & Ho, J. E. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.01.049 · Cited by 742
Cardiovascular risk in diabetes mellitus: Epidemiology, assessment and prevention
Wong, N. D., & Sattar, N. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00877-z · Cited by 495
Neuen, B. L., Fletcher, R. A., Heath, L., Perkovic, A., Vaduganathan, M., Badve, S. V., Tuttle, K. R., Pratley, R., Gerstein, H. C., Perkovic, V., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.071689 · Cited by 168
Obesity accelerates cardiovascular ageing
Ruperez, C., Madeo, F., de Cabo, R., Kroemer, G., & Abdellatif, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf216 · Cited by 73
Metadata
- Authors
- Packer, M.
- Venue
- Circulation
- Published
- 2022-11
- Volume
- 146
- Issue
- 18
- Pages
- 1383-1405
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W4307886872
- Cited by
- 425
- References
- 238
- FWCI
- 52.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.